PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Eptinezumab - Migraine (prevention)

PAD Profile : Eptinezumab - Migraine (prevention)

Keywords :
fully human IgG2 monoclonal antibody, anti-calcitonin gene-related peptides, CGRP, migraine prophylaxis, migraine prevention, episodic migraine, chronic migraine
Brand Names Include :
Vyepti

Traffic Light Status

Status 1 of 1.

Status :
Red
Formulations :
  • Intravenous infusion
Trust Alignment :
Primary Care
ASPH
RSCH
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
06 December 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Area Prescribing Committee agreed to adopt the South West London (SWL) migraine prophylaxis drug pathway for chronic and episodic migraine.

NOTE: updates and new additions to the pathway are provided in addendums at the end of the document. 

See the Migraine (prophylaxis) Drug Pathway for full information.

05 April 2023
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee recommends eptinezumab as a treatment option for preventing migraine in line with NICE TA871. Eptinezumab will be given a RED traffic light status for this indication. Prescribing will be by hospital specialists only, in line with NICE TA871. Primary care prescribers should ensure that patient medication records include any medicine for which prescribing remains the responsibility of secondary or tertiary care. This will ensure that GP records, which are accessed by other healthcare providers, are a true and accurate reflection of the patient's medication.

Associated BNF Codes

04. Central Nervous System
04.07.04. Antimigraine drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More